14,588 Shares in DaVita Inc. (NYSE:DVA) Bought by Weiss Asset Management LP

Weiss Asset Management LP bought a new position in DaVita Inc. (NYSE:DVA - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 14,588 shares of the company's stock, valued at approximately $2,391,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Atom Investors LP bought a new position in DaVita in the 3rd quarter valued at $4,094,000. Assenagon Asset Management S.A. grew its position in DaVita by 29.6% during the second quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company's stock valued at $6,942,000 after buying an additional 11,454 shares during the period. Quest Partners LLC purchased a new stake in DaVita during the third quarter worth about $669,000. MBB Public Markets I LLC bought a new stake in DaVita in the second quarter worth about $582,000. Finally, Centiva Capital LP boosted its stake in DaVita by 61.2% in the third quarter. Centiva Capital LP now owns 15,207 shares of the company's stock valued at $2,493,000 after acquiring an additional 5,776 shares during the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Performance

Shares of DaVita stock traded down $1.12 during trading hours on Friday, reaching $160.25. The company had a trading volume of 506,762 shares, compared to its average volume of 744,634. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a one year low of $103.40 and a one year high of $169.51. The firm has a market cap of $13.14 billion, a PE ratio of 17.29, a price-to-earnings-growth ratio of 0.92 and a beta of 0.90. The business has a fifty day simple moving average of $158.58 and a 200 day simple moving average of $150.23.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The company had revenue of $3.26 billion for the quarter, compared to analysts' expectations of $3.25 billion. During the same period in the previous year, the firm earned $2.85 EPS. The firm's quarterly revenue was up 4.6% compared to the same quarter last year. On average, analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on DVA shares. Truist Financial raised their price target on shares of DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research note on Monday, October 7th. Barclays boosted their target price on DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, DaVita has a consensus rating of "Hold" and a consensus price target of $161.80.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 50,000 shares of the business's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. The trade was a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.00% of the stock is currently owned by insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.